https://doi.org/10.55788/4a4d3cb6
APDS (activated PI3Kδ syndrome), also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) is a rare primary immunodeficiency caused by pathogenic variants in PIK3CD or PIK3R1, leading to PI3Kδ signalling hyperactivity. Clinical characteristics of APDS are lymphoproliferation, auto-immunity, immunodeficiency, and increased risk of lymphoma. Current treatment options include stem cell transplantation, immunoglobulin replacement therapy, and empirical treatment such as immunomodulatory, antibiotic, and antiviral therapy for symptom relief. Leniolisib is a small-molecule inhibitor of hyperactive PI3Kδ signalling [1].
Dr Koneti Rao (National Institute of Health, MD, USA) presented results from a phase 3, placebo-controlled, randomised clinical trial (NCT02435173) that evaluated the efficacy and safety of leniolisib in patients with APDS [2]. A total of 31 patients were randomised 2:1 to leniolisib (twice daily for 12 weeks) or placebo. Primary outcomes measures were the change from baseline in percentage of naïve B cells out of total B cells, and diameters in the index lesions (lymph nodes). Additional observations included changes in spleen size and cytopenia.
Leniolisib significantly increased the mean percentage of naïve B cells over time (from 40% at baseline to 65% at day 85), whereas no change was observed in the placebo arm (P=0.0006). Lymphadenopathy was significantly reduced in the leniolisib arm. In addition, leniolisib significantly decreased splenomegaly from baseline: differences of -13.5 cm2 (2D diameter) and -186.3 cm3 (3D diameter), whereas no changes were observed in the placebo arm. Cytopenia improved in 82% of patients receiving leniolisib, versus in 60% of patients receiving placebo.
Leniolisib was well tolerated, and no serious adverse events related to the study treatment were observed. However, leniolisib resulted in a transient neutropenia (nadir on day 15).
Based on these results, Dr Rao concluded that “leniolisib is safe, increases naïve B cells, decreases lymphadenopathy, decreases spleen size, and improves cytopenia.”
- Rao VK, et al. Blood 2017;130:2307–2316.
- Rao VK, et al. Hematological outcomes from a phase 3, placebo-controlled, randomized clinical trial of PI3K delta inhibitor leniolisib in patients with activated PI3K delta syndrome (APDS/PASLI). Abstract LB2369. EHA2022 Hybrid Congress, 09–12 June.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Skull lesions in Langerhans-cell histiocytosis usually resolve without treatment Next Article
Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin »
« Skull lesions in Langerhans-cell histiocytosis usually resolve without treatment Next Article
Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin »
Table of Contents: EHA 2022
Featured articles
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
AML
Pan-clonal score predicts first-line treatment response in AML
Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML
No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics
Lymphocytic Leukaemia & Lymphoma
New subtypes of oncogenic deregulation in childhood T-ALL
Triple-therapy improves PFS in fit, previously untreated CLL
Axi-cel superior to standard-of-care in older patients with relapsed/refractory large B-cell lymphoma
Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment
DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma
Myeloma
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
Triplet therapy plus early ASCT improves PFS in newly diagnosed multiple myeloma versus triplet therapy alone
Non-Cancerous Blood Disorders
Momelotinib induces a rapid and sustained improvement in haemoglobin levels in patients with myelofibrosis
Caplacizumab is safe and effective in patients with iTTP, also in the long term
Transfusion-dependent β-thalassaemia patients continue to benefit from luspatercept after 3 years of treatment
Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin
PI3Kδ inhibitor leniolisib improves symptoms in patients with APDS/PASLI
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy